News & Press: Latest News

MDMA Statement on Senate Passage of the “Opioid Crisis Response Act of 2018”

Tuesday, September 18, 2018  
Share |

MDMA Statement on Senate Passage of the “Opioid Crisis Response Act of 2018”

 

Washington, D.C. – Mark Leahey, President and CEO of the Medical Device Manufacturers Association (MDMA), issued the following statement regarding Senate passage of the “Opioid Crisis Response Act of 2018:”

Medical technology therapies and interventions have a proven track record of treating chronic and acute pain, and it is critical that they play a larger role in combating the opioid crisis that is crippling our nation.  This public health epidemic requires an ‘all hands on deck’ approach to address the various causes of opioid addiction and abuse, and this legislation includes various provisions to raise awareness of non-opioid and non-pharmacologic alternatives for pain management as well as to bolster the FDA’s ability to review promising medical devices that can help provide urgently needed solutions. 

“MDMA looks forward to working with Congress and the Administration to finalize legislation that ensures medical technologies are able to play a central role in managing patients’ pain and addressing the opioid crisis.”

###